Subjective ratings of appetite sensations were measured by a 100-mm visual analogue scale for parameters of hunger, fullness, satiety, and prospective food consumption pre- and 4-5h post-meal. Meal intake decreased on Day 2 (TZP 5 mg) and dose-dependently decreased with TZP vs. PBO on Day 51 (Figure). The proportion of meal occasions with ≥50% meal leftover was 0% (PBO) and 16.7% (TZP 5 mg) on Day 2 and 0% (PBO), 13.6% (TZP 5 mg), 18.2% (TZP 10 mg) and 30.0% (TZP 15 mg) on Day 51. There was a trend in decreasing hunger and fullness scores with all TZP doses vs. PBO on Day 51. However, satiety, prospective food consumption and overall appetite scores did not differ among groups. TZP dose-dependently reduced meal intake and demonstrated a trend in decreased hunger.”
Effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes
Diabetes, Clinical Therapeutics/New Technology — Incretin based therapies, June 2020